English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe results of a study published today in Nature Medicine show exciting immune responses in patients with operable esophageal or gastroesophageal cancers given neoadjuvant immunotherapy. The study results also show the potential for monitoring circulating tumor DNA as a predictor for future intervention.
Tag: Neoadjuvant Chemotherapy
Dual immunotherapy plus chemotherapy before surgery improves patient outcomes in operable lung cancer
In a Phase II trial led by researchers from The University of Texas MD Anderson Cancer Center, adding ipilimumab to a neoadjuvant, or pre-surgical, combination of nivolumab plus platinum-based chemotherapy, resulted in a major pathologic response (MPR) in half of all treated patients with early-stage, resectable non-small cell lung cancer (NSCLC).
New Study in JNCCN Suggests Way to Predict Outcomes with High Accuracy Prior to Surgery for Pancreatic Cancer Patients
New research in the September 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds the use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant prognostic benefit in objectively assessing neoadjuvant chemotherapy response in borderline resectable/locally advanced pancreatic cancer patients prior to surgery.
Less chemotherapy may have more benefit in rectal cancer
University of Colorado Cancer Center study presented at the 2020 Gastrointestinal Cancers Symposium shows patients with locally advanced rectal cancer receiving lower-than-recommended doses of neoadjuvant chemotherapy in fact saw their tumors shrink more than patients receiving the full dose.